Anti-CD8 abrogates effect of anti-CD4-mediated islet allograft survival in rat model. 1991

K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
Department of Medicine, Stanford University School of Medicine, California 94305-5111.

We studied the effects of anti-CD4 treatment of diabetic ACI rats on the induction of tolerance to allogeneic (Lewis) islet allografts. When given as a 4-day treatment regimen, OX38, a mouse anti-rat CD4 antibody, caused depletion of greater than 80% of CD4+ cells from the peripheral blood of treated rats. After induction of diabetes (a single high-dose bolus of streptozocin) and 3 days after the initiation of anti-CD4 immunotherapy, recipient ACI rats were transplanted with fully allogeneic (Lewis) islets of Langerhans via the portal circulation. These transplanted islets were capable of returning the anti-CD4-treated ACI recipients to normoglycemia, which was maintained indefinitely in the absence of further immunosuppression. In contrast, treatment of recipient rats with OX8, an anti-CD8 monoclonal antibody (MoAb), induced only a slight prolongation of graft survival (less than or equal to 30 days). Further characterization of the cellular requirements for the induction of long-term transplantation survival revealed that successful pretransplantation anti-CD4 therapy could be ablated by the coincident treatment of recipient rats with depleting levels of anti-CD8 MoAb. These data point to the necessity of a regulator CD8+ cell in the induction of anti-CD4-mediated transplantation survival in this rat model of islet transplantation.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D008297 Male Males
D011912 Rats, Inbred ACI An inbred strain of rat that is widely used in BIOMEDICAL RESEARCH. Applications include the study of spontaneous NEOPLASMS; CHRONIC KIDNEY DISEASES, and CONGENITAL ABNORMALITIES. Rats, Inbred A x C 9935 Irish,Rats, ACI,ACI Rat,ACI Rat, Inbred,ACI Rats,ACI Rats, Inbred,Inbred ACI Rat,Inbred ACI Rats,Rat, ACI,Rat, Inbred ACI
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
January 1993, Transplantation,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
April 1993, Transplantation,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
June 1994, Transplantation proceedings,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
July 1990, Transplantation,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
June 1997, Journal of autoimmunity,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
February 1989, Transplantation proceedings,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
January 1996, Transplantation,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
December 1992, Transplantation,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
January 1997, Transplantation proceedings,
K Seydel, and J Shizuru, and D Grossman, and A Wu, and S Alters, and C G Fathman
February 1993, Transplantation proceedings,
Copied contents to your clipboard!